Selective reduction of supported CuO to Cu2O was realized using the strategy of vapor-induced reduction, in which HCHO/H2O vapor diffuses into the pores of the support and interacts with predispersed CuO. This new strategy allows the fabrication of supported cuprous sites at much lower temperatures within a short time, avoids the formation of Cu(0) with a Cu(I) yield of nearly 100%, and results in materials with good adsorption performance, which is impossible to achieve by conventional methods.

Metal−organic frameworks (MOFs) show high potential in adsorptive removal of aromatic sulfur compounds; however, the crucial factors affecting the adsorption performances are scarcely clarified. In the present study, three classic aromatic sulfur compounds (i.e., thiophene, benzothiophene, and 4,6-dimethyldibenzothiophene) as well as five typical MOFs (i.e., MOF-5, HKUST-1, MIL-53(Fe), MIL-53(Cr), and MIL-101(Cr)) were selected for study. The adsorptive desulfurization performances of MOFs were investigated by using a fixed-bed adsorption system. In the case of thiophene, the adsorption capacity of MOFs decreases in the order MIL-53(Cr) > HKUST-1 > MOF-5 > MIL-53(Fe) > MIL-101(Cr). For the first time, the adsorbate−adsorbent interaction was examined in detail by using infrared spectra and temperature-programmed desorption. Such an interaction was demonstrated to be the most important factor affecting adsorption performance. When the molecular size of aromatic sulfur compounds is comparable to or smaller than the window diameter of MOFs, the influence of window diameter becomes apparent. It is surprising to find that the adsorbate−adsorbent interaction plays a major role, which is responsible for the poor adsorption performance of MIL-101(Cr) with quite high porosity. Therefore, metal sites and structure that contribute to the adsorbate−adsorbent interaction should be considered to be the most significant factor aiming to develop new MOFs for adsorptive desulfurization.

A facile one-step method was proposed for the successful synthesis of Ag-nanoparticle-loaded mesoporous silica SBA-15 composites, where silver ions and their corresponding reductant aniline were added in the traditional synthetic system of mesoporous silica SBA-15 containing P123 as the surfactant and TEOS as the silica source. Mesoporous silica SBA-15 and Ag nanoparticles were spontaneously formed with Ag nanoparticles embedded in channels and even implanted in frameworks of mesoporous silica SBA-15. A tentative formation process was then proposed according to experimental observations. Furthermore, catalytic activities of Ag-nanoparticle-loaded silica SBA-15 composites toward the reduction of 4-nitrophenol in the presence of NaBH(4) and the reduction of H(2)O(2) were also investigated.

Introduction: During nonreciprocal/reciprocal translocation process, 5 0 -anaplastic lymphoma kinase (ALK) sometimes gets retained in the genome and is detectable by next-generation sequencing; however, no study has investigated its clinical significance. Our study aimed to assess the impact of harboring 5 0 -ALK on the efficacy of crizotinib.Methods: A total of 150 patients with next-generation sequencing-identified ALK-rearranged NSCLC from March 2014 to July 2018 at the Hunan Cancer Hospital were enrolled in this study. The efficacy of crizotinib as first-line therapy was evaluated in 112 patients according to the retention of 5 0 -ALK.Results: Among the 150 patients with NSCLC, nonreciprocal/reciprocal translocation was detected in 18.7% (28 of 150), and 3 0 -ALK fusion alone was detected in 81.3% (122 of 150). Among the 112 patients who received firstline crizotinib, 89 had 3 0 -ALK fusion alone (79 echinoderm microtubule associated protein-like 4 [EML4]-ALK and 10 non-EML4-ALK), and 23 had nonreciprocal/ reciprocal ALK translocation. Among the patients with nonreciprocal/reciprocal ALK translocation, three patients harbored dual concurrent 3 0 -ALK fusions. Patients with nonreciprocal/reciprocal ALK translocation had higher incidence of brain metastasis at baseline than those with 3 0 -ALK fusion alone (39.1% versus 13.4%, p ¼ 0.028). Crizotinib-treated patients with nonreciprocal/ reciprocal ALK translocation had significantly shorter median progression-free survival (PFS) compared with patients carrying 3 0 -ALK fusion alone (6.1 m versus 12.0 m, p ¼ 0.001) or with EML4-ALK fusion alone (6.1 m versus 12.6 m, p ¼ 0.001). Multivariate analysis revealed that harboring nonreciprocal/reciprocal ALK translocation was an independent predictor of worse PFS for crizotinib-treated ALK-rearranged NSCLC (p ¼ 0.0046).